Rapport Therapeutics (NASDAQ: RAPP) details RAP-219 and epilepsy plans

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. filed a current report describing new investor communications. On January 7, 2026, the company issued a press release titled “Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline,” which is furnished as an exhibit.

On the same date, Rapport updated its corporate presentation for use with investors, analysts and others, and made it available on the Investors section of its website. The updated presentation is also attached as an exhibit to this report.

0002012593false00020125932026-01-072026-01-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 07, 2026

Rapport Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42121	88-0724208
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
99 High Street Suite 2100
Boston, Massachusetts				02110
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 321-8020

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		RAPP		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 7, 2026, Rapport Therapeutics, Inc. (the “Company” or “Rapport”) issued a press release titled “Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On January 7, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the “Investors” page of the Company’s website at www.rapportrx.com. A copy of the presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1			Press Release issued by Rapport Therapeutics, Inc. on January 7, 2026, furnished herewith.
99.2			Corporate Presentation of Rapport Therapeutics, Inc.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Rapport Therapeutics, Inc.
Date:	January 7, 2026	By:	/s/ Troy Ignelzi
			Troy Ingelzi Chief Financial Officer

FAQ

What did Rapport Therapeutics (RAPP) disclose in this 8-K filing?

Rapport Therapeutics disclosed that it issued a new press release about accelerating its RAP-219 program, expanding its epilepsy portfolio, and continuing progress across its pipeline, and that it updated its corporate presentation for investors.

What is the title of Rapport Therapeutics’ new press release mentioned in the 8-K?

The press release is titled “Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline.”

How did Rapport Therapeutics (RAPP) share its updated corporate presentation?

Rapport Therapeutics made its updated corporate presentation available on the “Investors” page of its website at www.rapportrx.com and attached it as Exhibit 99.2 to the report.

Are the press release and presentation considered filed or furnished by Rapport Therapeutics?

The materials under Item 7.01, including the press release in Exhibit 99.1, are furnished and are not deemed “filed” for purposes of Section 18 of the Exchange Act, except if specifically incorporated by reference elsewhere.

Which exhibits are included with this Rapport Therapeutics 8-K?

The exhibits include a press release issued on January 7, 2026 (Exhibit 99.1), the corporate presentation of Rapport Therapeutics, Inc. (Exhibit 99.2), and the cover page interactive data file (Exhibit 104).

Where can investors find more detailed information about Rapport Therapeutics’ RAP-219 program and epilepsy portfolio?

Investors can review the press release furnished as Exhibit 99.1 and the corporate presentation attached as Exhibit 99.2 and posted on the company’s Investors webpage for more detailed information.